<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01296971</url>
  </required_header>
  <id_info>
    <org_study_id>ML25246</org_study_id>
    <nct_id>NCT01296971</nct_id>
  </id_info>
  <brief_title>A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)</brief_title>
  <official_title>Open-label, Multicenter, Non-Comparative Prospective Study to Assess the Safety of Individualized Combination Therapy With Ribavirin And Peginterferon Alfa-2a (40 kD) in Patients With Chronic Hepatitis C (CHC) (MASTER Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label, non-comparative study will assess the safety and tolerability of
      individualized combination therapy with Copegus (ribavirin) and Pegasys (peginterferon
      alfa-2a) in patients with chronic hepatitis C. Patients with hepatitis C virus (HCV) genotype
      1 (Group A) will receive Copegus 1'000 mg or 1'200 mg daily orally for 24-72 weeks. For
      patients with genotype 2 or 3 HCV (Group B) the Copegus dose will be 800 mg daily for 16-48
      weeks. Patients who had previously received standard or pegylated interferons but were
      non-responders or with relapse (Group C) will receive Copegus 1'000 mg or 1'200 mg daily for
      up to 72 weeks. Concomitant therapy with Pegasys 180 mcg subcutaneously weekly will be given
      to all patients. Anticipated time on study treatment is up to 72 weeks with a 24-week
      follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    study was not started due to an administrative reason on the part of the local Health Authority
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of individualized Copegus treatment in combination with Pegasys: Adverse events</measure>
    <time_frame>up to 96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of dose reductions in case of adverse events on sustained virological response (HCV-RNA)</measure>
    <time_frame>up to 96 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological response/sustained virological response (serum HCV RNA levels)</measure>
    <time_frame>24 weeks after treatment completion</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>genotype 1, treatment-naive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>genotype 2 and 3, treatment-naive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all genotypes, non-responders or relapses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a [Pegasys]</intervention_name>
    <description>180 mcg sc weekly</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin [Copegus]</intervention_name>
    <description>1'000/1'200 mg daily orally, 24 - 72 weeks</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin [Copegus]</intervention_name>
    <description>800 mg daily orally, 16 - 48 weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;/= 18 years of age

          -  Chronic hepatitis C

          -  Measurable serum HVC RNA levels

          -  Compensated liver disease (Child-Pugh class A)

          -  Treatment-naive for standard or pegylated interferons, or non-responder or relapsing

        Exclusion Criteria:

          -  Concomitant hepatitis A or B

          -  History of chronic liver disease not caused by hepatitis C virus

          -  Hepatocellular carcinoma

          -  History or signs of esophageal varices haemorrhage or other conditions indicative of
             decompensated liver disease

          -  Treatment with any systemic anti-tumor or immunomodulatory agent (including steroids
             at doses exceeding physiological ones, and radiotherapy) within 6 months prior to
             first dose of study drug

          -  Pregnant or lactating women, or men whose partners are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2010</study_first_submitted>
  <study_first_submitted_qc>February 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2011</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

